Jing WANG, Yan ZHU, Zhongwei LIU, et al. Dynamic analysis of serum markers of HBV in 302 infants of pregnant women with HBV infection[J]. Journal of Army Medical University, 2022, 44(8): 797-804.
DOI:
Jing WANG, Yan ZHU, Zhongwei LIU, et al. Dynamic analysis of serum markers of HBV in 302 infants of pregnant women with HBV infection[J]. Journal of Army Medical University, 2022, 44(8): 797-804. DOI: 10.16016/j.2097-0927.202202052.
Dynamic analysis of serum markers of HBV in 302 infants of pregnant women with HBV infection
To investigate the dynamic changes of HBV serum markers (HBV-M) in pregnant women with HBV infection and its clinical significance.
Methods
2
A total of 302 infants delivered by HBV infected pregnant women registered and examined in our hospital from January 2016 to April 2020 were included. Serum HBV-M and HBV-DNA were detected in the 302 pregnant women during late pregnancy and in their infants aged 6~12 months (time point 1
T1) and 20~30 months (time point 2
T2). The dynamic changes and influencing factors were analyzed.
Results
2
For the infants
HBsAg was negative at both time points
and there were 301 cases of anti-HBs positive
3 cases of HBeAg positive
46 cases of anti-HBe positive and 207 cases of anti-HBc positive at T1
and all these indicators were decreased gradually with the age of infants. At T2
8 cases of anti-HBs positive turned negative
while those of HBeAg
anti-HBe and anti-HBc positive turned negative. The lower the titer of T1 anti-HBs was
the more likely it was to turn negative. At T2
the titer of anti-HBs was not related to feeding mode
delivery mode and mother HBV DNA level.
Conclusion
2
Serum HBeAg
anti-HBe and anti-HBc are all derived from the mother and metabolized gradually. The success rate of mother-to-child prevention for HBV infected pregnant women is quite high. If the titer of the initial test is relatively low
the time of reexamination should be shortened.
关键词
Keywords
references
World Health Organization. Hepatitis B[R]. 2017-07-28.
GENTILE I, BORGIA G. Vertical transmission of hepatitis B virus: challenges and solutions[J]. Int J Womens Health, 2014, 6: 605-611. DOI: 10.2147/IJWH.S51138.
WANG T, WANG M Y, DUAN G H, et al . Discrepancy in impact of maternal milk on vertical transmission between hepatitis B virus and human cytomegalovirus[J ] . Int J Infect Dis, 2015, 37: 1-5. DOI: 10.1016/j.ijid.2015.06.002.
BZOWEJ N H. Optimal management of the hepatitis B patient who desires pregnancy or is pregnant[J]. Curr Hepat Rep, 2012, 11(2): 82-89. DOI: 10.1007/s11901-012-0130-x.
YIN Y Z, WU L L, ZHANG J, et al . Identification of risk factorsassociated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virus[J ] . J Infect, 2013, 66(5): 447-452. DOI: 10.1016/j.jinf.2012.12.008.
MA X Y, SUN J Y, CAI H D. Effects of states of HBV infection in mothers' infected with hepatitis B virus on serum markers of HBV in neonates[J]. Chin J Exp Clin Infect Dis Electron Ed, 2014, 8(3): 352-355. DOI: 10.3877/cma.j.issn.1674-1358.2014.03.012.
WANG J S. Transformation of hepatitis B serologic markers in babies born to hepatitis B surface antigen positive mothers[J]. World J Gastroenterol, 2005, 11(23): 3582. DOI: 10.3748/wjg.v11.i23.3582.
CUI H C, YAN Y P, SHAO Z J, et al . Dynamic changes of hepatitis B virus markers in infants of HBsAg positive mothers[J ] . Chin J Infect Dis, 2009, 27(2): 118-122. DOI: 10.3760/cma.j.issn.1000-6680.2009.02.016.
SHAO Z J, ZHANG L, XU J Q, et al . Mother-to-infant transmission of hepatitis Bvirus: a Chinese experience[J ] . J Med Virol, 2011, 83(5): 791-795. DOI: 10.1002/jmv.22043.
WANG G Q, WANG F S, CHENG J, et al . The guidelines of prevention and treatment for chronic hepatitis B: a 2015 upd ate[J ] . Chin J Liver Dis(Electr Version), 2019, 37(12): 711-736.
HUANG H Y, XU C Y, LIU L H, et al . Increased protection of earlier use of immunoprophylaxis in preventing perinatal transmission of hepatitis B virus[J ] . Clin Infect Dis, 2021, 73(9): e3317-e3323. DOI: 10.1093/cid/ciaa898.
WHITFORD K, LIU B, MICALLEF J, et al . Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis[J ] . Bull World Health Organ, 2018, 96(7): 484-497. DOI: 10.2471/BLT.17.205153.
QAWASMI M, SAMUH M, GLEBE D, et al . Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood[J ] . Hum Vaccin Immunother, 2015, 11(7): 1717-1724. DOI: 10. 1080/21645515.2015.1041687.
WANG C, WANG C, JIA Z F, et al . Protective effect of an improved immunization practice of mother-to-infant transmission of hepatitis B virus and risk factors associated with immunoprophylaxis failure[J ] . Medicine, 2016, 95(34): e4390. DOI: 10.1097/MD.0000000000004390.
YUE X, GE C, ZHUGE S, et al . Changes and analysis of anti-HBs titres after primary immunization in 1- to 16-year-old Chinese children: a hospital-based study[J ] . J Viral Hepat, 2018, 25(4): 373-380. DOI: 10.1111/jvh.12818.
YAN K, CAI W, CAO F, et al . Genetic effects have a dominant role on poor responses to infant vaccination to hepatitis B virus[J ] . J Hum Genet, 2013, 58(5): 293-297. DOI: 10.1038/jhg.2013.18.
JIANG M, ZHU B, YAO Q, et al . Anti-HBs levels in children under the age of two years born to HBV carrier mothers after immunoprophylaxis: a multicenter cross-sectional study[J ] . BMC Pediatr, 2021, 21: 492. DOI: 10.1186/s12887-021-02967-8.
LI S H, YUE Y F, ZHAO X G, et al . Quantification and expression of human annexin Ⅴ in kinds of placenta[J ] . Chin J Birth Heal Hered, 2005, 13(10): 31-33. DOI: 10.3969/j.issn.1006-9534.2005.10.013.
ARAKAWA K, TSUDA F, TAKAHASHI K, et al . Maternofetal transmission of IgG-bound hepatitis B e antigen[J ] . Pediatr Res, 1982, 16(3): 247-250. DOI: 10.1203/00006450-198203000-00017.
SRSF1 inhibits HBV replication by enhancing the stability of P53 in cell models
Effect of interferons on expression of adenosine deaminase acting on RNA 1 and hepatitis B virus replication in human hepatocellular carcinoma cells in vitro
Primary identification of compounds targeting hepatitis B virus capsid formation from the FDA approved drugs
Related Author
LIU Jiajun
LONG Shaoyuan
HU Jieli
CUI Jing
Yimin LI
Lin YUAN
Shengyong YANG
Yuan HU
Related Institution
Key Laboratory of Molecular Biology for Infectious Diseases of Ministry of Education, Chongqing Medical University
First Affiliated Hospital, Air Force Medical University
Key Laboratory of Molecular Biology on Infectious Diseases of Ministry of Education, Chongqing Medical University
Department of Pathogen Biology, Molecular Medicine and Tumor Research Center, College of Basic Medical Sciences, Chongqing Medical University
Key Laboratory of Molecular Biology on Infectious Diseases of Ministry of Education, Chongqing Medical University